Protein-Based Nanocarriers and Nanotherapeutics for Infection and Inflammation
The Journal of Pharmacology and Experimental Therapeutics · 2024-01 · 388 (1) · 91-109
DOI: 10.1124/jpet.123.001673 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024-01. Verfasst von Nupur Nagar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences and Bioengineering (N.N., G.N., K.M.P.) and Centre for Nanotechnology (K.M.P.), Indian Institute of Technology Roorkee, Roo…. Hauptthemen laut MEDLINE: Drug Delivery Systems, Nanoparticles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 207 Literaturangaben.
Abstract (Originalsprache)
Infectious and inflammatory diseases are one of the leading causes of death globally. The status quo has become more prominent with the onset of the coronavirus disease 2019 (COVID-19) pandemic. To combat these potential crises, proteins have been proven as highly efficacious drugs, drug targets, and biomarkers. On the other hand, advancements in nanotechnology have aided efficient and sustained drug delivery due to their nano-dimension-acquired advantages. Combining both strategies together, the protein nanoplatforms are equipped with the advantageous intrinsic properties of proteins as well as nanoformulations, eloquently changing the field of nanomedicine. Proteins can act as carriers, therapeutics, diagnostics, and theranostics in their nanoform as fusion proteins or as composites with other organic/inorganic materials. Protein-based nanoplatforms have been extensively explored to target the major infectious and inflammatory diseases of clinical concern. The current review comprehensively deliberated proteins as nanocarriers for drugs and nanotherapeutics for inflammatory and infectious agents, with special emphasis on cancer and viral diseases. A plethora of proteins from diverse organisms have aided in the synthesis of protein-based nanoformulations. The current study specifically presented the proteins of human and pathogenic origin to dwell upon the field of protein nanotechnology, emphasizing their pharmacological advantages. Further, the successful clinical translation and current bottlenecks of the protein-based nanoformulations associated with the infection-inflammation paradigm have also been discussed comprehensively. SIGNIFICANCE STATEMENT: This review discusses the plethora of promising protein-based nanocarriers and nanotherapeutics explored for infectious and inflammatory ailments, with particular emphasis on protein nanoparticles of human and pathogenic origin with reference to the advantages, ADME (absorption, distribution, metabolism, and excretion parameters), and current bottlenecks in development of protein-based nanotherapeutic interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biosciences and Bioengineering (N.N., G.N., K.M.P.) and Centre for Nanotechnology (K.M.P.), Indian Institute of Technology Roorkee, Roorkee, Uttarakhand, India; and Cellular and Molecular Neurobiology Unit…
ORCID-Profile: Amit Mishra
Zitieren
APA
Nagar, N., Naidu, G., Mishra, A., & Poluri, K. M. (2024). Protein-Based Nanocarriers and Nanotherapeutics for Infection and Inflammation. The Journal of Pharmacology and Experimental Therapeutics, 388(1), 91-109. https://doi.org/10.1124/jpet.123.001673
Vancouver
Nagar N, Naidu G, Mishra A, Poluri KM. Protein-Based Nanocarriers and Nanotherapeutics for Infection and Inflammation. The Journal of Pharmacology and Experimental Therapeutics. 2024;388(1):91-109. doi:10.1124/jpet.123.001673
BibTeX
@article{Nagar2024,
author = {Nagar, Nupur and Naidu, Goutami and Mishra, Amit and Poluri, Krishna Mohan},
title = {Protein-Based Nanocarriers and Nanotherapeutics for Infection and Inflammation},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
year = {2024},
volume = {388},
number = {1},
pages = {91--109},
doi = {10.1124/jpet.123.001673}
}
EUVIMED